dengu
viru
major
human
pathogen
respons
million
infect
yearli
rna
virus
daunt
challeng
antivir
design
exist
due
high
error
rate
rnadepend
rna
synthesi
inde
treatment
dengu
viru
infect
nucleosid
analog
result
expect
genet
select
resist
virus
tissu
cultur
mice
howev
function
oligomer
core
protein
inhibit
detect
select
drug
resist
tissu
cultur
mice
detect
despit
presenc
drugresist
variant
popul
suppress
select
drugresist
viru
correl
cooligomer
target
drugsuscept
drugresist
core
protein
concept
domin
drug
target
inhibit
oligomer
viral
assemblag
lead
format
drugsuscept
chimera
therefor
use
prevent
outgrowth
drug
resist
dengu
viru
infect
import
drug
resist
major
hurdl
develop
effect
antivir
especi
direct
rna
virus
found
one
use
concept
genet
domin
defect
subunit
turn
cousin
enemi
ie
thwart
outgrowth
drugresist
viral
genom
soon
gener
requir
deliber
target
larger
assemblag
would
otherwis
rare
consid
antivir
research
citat
mateo
r
nagamin
cm
kirkegaard
k
suppress
drug
resist
dengu
viru
mbio
f
positivestrand
rna
virus
consid
prioriti
pathogen
dengu
viru
west
nile
viru
yellow
fever
viru
chikungunya
viru
sever
acut
respiratori
syndrom
coronaviru
hepat
viru
caus
agent
sever
viral
encephalopathi
antivir
pharmaceut
exist
among
negativestrand
rna
virus
devast
ebola
outbreak
west
africa
threat
new
influenza
viru
pandem
highlight
import
develop
effect
vaccin
therapeut
target
highli
adapt
genet
labil
rna
virus
dengu
viru
origin
confin
tropic
subtrop
area
begun
spread
outsid
former
geograph
limit
due
chang
ecolog
mosquito
popul
face
urban
global
warm
previous
denguefre
countri
risk
japan
report
case
dengu
fever
year
suffer
diseas
outbreak
due
expand
rang
four
dengu
viru
serotyp
like
individu
infect
previous
one
serotyp
becom
infect
anoth
antibodi
first
infect
neutral
newli
infect
serotyp
enhanc
symptom
increas
probabl
dengu
hemorrhag
fever
sever
often
fatal
form
diseas
given
demograph
infect
dengu
viru
emerg
pathogen
highli
desir
reduc
complex
expens
vaccin
treatment
positivestrand
rna
viru
effect
pharmacolog
treatment
exist
hepat
c
viru
hcv
serv
illustr
current
paradigm
success
antivir
develop
antihcv
drug
target
proteas
nonstructur
protein
polymeras
current
avail
high
cost
drug
individu
treatment
averag
per
patient
contribut
increas
prescript
drug
spend
unit
state
alon
sinc
paradigm
sustain
mani
infect
threaten
human
health
product
worldwid
emerg
drugresist
rna
virus
requir
first
virus
gener
subsequ
select
pressur
drug
treatment
promot
select
amplif
rna
virus
display
errorpron
replic
strategi
error
rate
per
nucleotid
copi
result
accumul
mutat
frequenc
greater
per
round
intracellular
quasispeci
gener
larg
amount
preexist
divers
ensur
inoculum
dengu
virus
genom
mutat
nucleotid
posit
present
understand
approach
reduc
outgrowth
drugresist
viral
genom
aim
reduc
frequenc
gener
genom
viral
escap
combin
therapi
exampl
requir
multipl
mutat
confer
resist
drug
combin
similarli
protein
function
human
host
target
may
way
viru
escap
depend
human
host
factor
therefor
viral
genom
infrequ
differ
approach
suppress
drug
resist
assum
drugresist
genom
inevit
gener
drug
target
identifi
select
drug
resist
blunt
usual
drug
resist
domin
ie
newli
gener
drugresist
viral
genom
amplifi
select
presenc
drug
even
though
gener
cell
drugsuscept
parent
sibl
howev
case
defect
genom
drugsuscept
genom
domin
often
occur
defect
protein
form
highord
oligom
cell
contain
defect
function
genom
final
assemblag
contain
defect
function
subunit
often
chimer
structur
nonfunct
appli
principl
viral
infect
shown
although
mutant
polioviru
genom
resist
capsid
inhibitor
could
readili
gener
select
cultur
cell
mice
term
viral
target
polioviru
capsid
drugsuscept
genom
domin
drugresist
sibl
domin
drug
target
identifi
domin
drug
target
dengu
viru
genom
test
effect
two
differ
antivir
compound
nucleosid
analog
inhibit
viral
polymeras
planar
compound
inhibit
function
core
protein
oligomer
structur
protein
tissu
cultur
mice
select
virus
readili
observ
howev
virus
resist
select
tissu
cultur
presenc
drugsuscept
viru
resist
virus
emerg
treatment
infect
mice
thu
dengu
viru
core
protein
domin
drug
target
pharmaceut
target
less
like
plagu
emerg
resist
viru
identifi
potenti
domin
drug
target
dengu
viru
sought
publish
antivir
compound
target
oligomer
viral
structur
byrd
et
al
report
inhibit
four
dengu
viru
serotyp
compound
term
identifi
highthroughput
screen
fig
dengu
viru
core
protein
determin
compound
target
direct
bind
experi
map
drugresist
mutat
code
sequenc
core
protein
gener
bulk
rtpcr
rna
extract
supernat
singli
doubli
infect
cell
wildtyp
viru
engin
contain
silent
aflii
restrict
site
core
code
region
g
amplicon
cleav
aflii
run
agarosetb
gel
proport
resist
suscept
genom
determin
percentag
uncleav
cleav
pcr
product
respect
result
shown
repres
exampl
coinfect
wildtyp
viru
data
shown
averag
standard
deviat
result
two
three
biolog
replic
statist
analysi
yield
drugresist
viru
coinfect
compar
singl
infect
via
unpair
student
test
fig
b
even
domin
drug
target
drugresist
virus
readili
select
necessari
mutat
preexist
inoculum
stock
passag
cultur
cell
low
multipl
infect
moi
preexist
variant
infect
cell
select
absenc
potenti
domin
wildtyp
protein
question
variant
newli
aris
test
whether
resist
suscept
domin
sever
genom
present
cell
infect
monolay
cell
mixtur
suscept
resist
virus
presenc
fig
mix
infect
design
mimic
select
newli
aris
drugresist
variant
infect
anim
gener
new
drugresist
genom
polymeras
error
occur
within
cell
alreadi
contain
parent
case
progeni
genom
thu
drugresist
genom
cell
origin
outnumb
drugsuscept
rel
amount
mutant
viru
kept
constant
averag
ffu
focusform
unit
per
cell
poisson
distribut
would
predict
cell
would
uninfect
rest
infect
one
two
drugresist
virus
number
wildtyp
virus
per
cell
rang
averag
ffucel
moi
almost
cell
infect
wildtyp
viru
one
cycl
infect
h
supernat
harvest
yield
total
viru
determin
addit
increas
amount
drugsuscept
wildtyp
viru
result
dosedepend
decreas
total
resist
viru
fig
even
cell
infect
one
drugresist
one
drugsuscept
viru
yield
drugresist
viru
significantli
reduc
fig
therefor
core
protein
inhibitor
drug
suscept
genet
domin
test
whether
reduct
accumul
encapsid
rna
mimick
reduct
infect
viral
rna
extract
viru
prepar
shown
fig
quantifi
quantit
revers
transcriptionpcr
qrtpcr
fig
cdna
wildtyp
viru
engin
contain
new
restrict
site
proport
drugsuscept
drugresist
genom
could
determin
molecularli
fig
g
aflii
restrict
digest
amplifi
cdna
product
result
chang
total
drugresist
rna
singl
infect
versu
coinfect
fig
therefor
domin
inhibit
product
infecti
viru
caus
failur
synthes
viral
rna
packag
secret
particl
instead
particl
gener
noninfecti
consist
mechan
propos
inhibit
ie
target
core
protein
assembl
virion
morphogenesi
biochem
domin
core
protein
like
mechan
abil
drugsuscept
core
protein
inhibit
function
drugresist
core
protein
format
chimer
oligom
test
whether
drugsuscept
drugresist
protein
could
coassembl
cellular
local
fig
singl
infect
coinfect
monitor
scatturo
et
al
found
previous
wildtyp
core
protein
predomin
associ
cytoplasm
membran
absenc
fig
top
row
presenc
wildtyp
core
protein
also
found
nuclear
fraction
might
contribut
compound
antivir
activ
contrast
figur
show
expect
amount
core
membran
associ
pattern
addit
fig
left
observ
pattern
fig
right
instead
mimick
drugsuscept
viru
alon
fig
left
therefor
wildtyp
drugsuscept
phenotyp
domin
drugresist
phenotyp
presenc
drugresist
protein
fraction
differ
presenc
drugsuscept
protein
support
hypothesi
two
kind
protein
coassembl
mutat
methyltransferas
domain
confer
resist
nucleosid
inhibitor
nucleosid
analog
also
term
fig
origin
develop
inhibitor
hepat
c
viru
polymeras
also
display
antivir
activ
dengu
viru
serotyp
cultur
cell
mice
inhibit
dengu
viru
serotyp
cell
shown
fig
select
virus
resist
dengu
viru
pool
grown
mosquito
cell
serial
passag
cell
presenc
absenc
increas
concentr
passag
multipl
infect
ffu
per
cell
allow
drugresist
variant
propag
absenc
coinfect
drugsuscept
viru
amount
viral
amplif
passag
display
ratio
total
output
viru
initi
inoculum
fig
sequenc
analysi
passag
virus
reveal
mutat
popul
ident
drugtreat
untreat
popul
tabl
mutat
like
confer
growth
advantag
cell
one
proven
use
adapt
mammalian
cell
line
r
dean
et
al
unpublish
data
notabl
two
viral
pool
passag
presenc
acquir
mutat
code
region
pool
pool
tabl
test
individu
mutat
select
resist
inhibitor
black
bar
control
mammalian
cultur
adapt
mosquitogrown
viru
initi
popul
also
passag
presenc
dmso
solvent
white
bar
passag
two
result
viru
pool
dmsopassag
counterpart
harvest
sequenc
adapt
mutat
found
popul
tabl
drugtreat
popul
passag
five
time
uniqu
mutat
popul
popul
found
shown
fold
amplif
passag
ratio
output
input
viru
c
wildtyp
virus
use
infect
bhk
cell
absenc
presenc
indic
yield
h
shown
spacefil
model
residu
threedimension
structur
dengu
viru
serotyp
protein
residu
serotyp
use
studi
align
residu
serotyp
respect
methyltransferas
domain
shown
yellow
gdd
residu
polymeras
activ
site
shown
blue
confer
signific
resist
compar
wildtyp
viru
fig
interestingli
mutat
map
methyltransferas
domain
protein
fig
thu
like
either
inhibit
methyltransferas
activ
alloster
interact
methyltransferas
polymeras
domain
reliev
inhibit
polymeras
activ
site
resist
genet
domin
determin
whether
resist
suscept
domin
seri
coinfect
suscept
virus
perform
conduct
similarli
experi
suscept
virus
shown
fig
growth
fix
amount
ffucel
drugresist
viru
monitor
either
alon
presenc
variou
amount
wildtyp
drugsuscept
viru
fig
infect
continu
singl
cycl
infect
presenc
supernat
titer
determin
absenc
measur
amount
total
viru
presenc
measur
amount
resist
viru
infect
isol
drugresist
virus
replic
presenc
drug
fig
c
left
upon
coinfect
drugsuscept
viru
titer
drugresist
viru
decreas
viru
fig
instead
yield
drugresist
drugsuscept
virus
increas
increas
moi
thu
drugresist
viru
rescu
drugsuscept
viru
drug
resist
domin
domin
drugresist
viru
observ
even
moi
drugsuscept
viru
higher
moi
virus
increas
determin
whether
accumul
viral
rna
deriv
drugsuscept
drugresist
genom
mirror
infecti
viru
yield
total
rna
determin
qrtpcr
proport
genom
quantifi
fig
viru
total
rna
accumul
increas
amount
total
input
viru
allel
fig
c
show
genet
domin
virus
due
rescu
wildtyp
rna
synthesi
treatment
mice
lead
select
drugresist
virus
tissu
cultur
experi
provid
evid
choic
drug
target
either
allow
suppress
select
drugresist
virus
first
intracellular
infecti
cycl
quantifi
frequenc
drugresist
virus
multipl
round
amplif
occur
murin
infect
need
mous
model
gave
rise
high
viral
yield
frequent
use
mous
model
dengu
viru
infect
intraven
inocul
strain
ifnar
ifngr
alpha
gamma
interferon
ifn
defici
mice
viru
could
readili
detect
spleen
infect
mice
day
postinfect
fig
ifnar
ifngr
mice
also
suscept
dengu
viru
infect
yield
viru
obtain
spleen
follow
inoculum
averag
higher
fig
higher
yield
facilit
detect
subpopul
drugresist
virus
employ
ifnar
ifngr
mice
measur
drugresist
virus
treatment
dengu
virusinfect
mice
ask
whether
virus
could
select
murin
infect
ifnar
ifngr
mice
inocul
dengu
viru
treat
oral
vehicl
solut
control
twice
daili
day
describ
previous
treatment
led
signific
decreas
dengu
viru
yield
fig
detect
emerg
drug
resist
spleen
homogen
control
mice
dilut
use
infect
fresh
monolay
cell
presenc
fig
day
supernat
titer
determin
rna
quantifi
strikingli
amplif
viru
fig
rna
popul
fig
observ
select
resist
murin
infect
document
select
resist
murin
infect
ifnar
ifngr
mice
infect
treat
oral
twice
daili
mgkg
bodi
weight
day
treatment
significantli
decreas
total
viral
yield
fig
determin
whether
inhibitori
pressur
led
select
drugresist
virus
drugresist
viru
rna
quantifi
infect
viru
control
mice
show
increas
drug
resist
passag
presenc
drug
howev
viru
mice
show
significantli
amplif
drugresist
virus
fig
rna
fig
amount
drug
resist
observ
correl
somewhat
amount
select
pressur
exert
fig
open
symbol
howev
alon
explain
larg
increas
resist
observ
mice
highli
signific
select
resist
contrast
lack
select
observ
oligomer
core
protein
target
dengu
viru
grow
primarili
monocyt
macrophag
dendrit
cell
infect
human
mice
intraven
inocul
perform
viru
travel
directli
spleen
primarili
infect
macrophag
margin
zone
upon
infect
natur
intraderm
rout
hand
dendrit
cell
present
peripheri
becom
infect
migrat
spleen
fig
either
case
lymph
node
spleen
viru
replic
spread
local
nearbi
cell
includ
red
pulp
macrophag
spleen
dissemin
bloodstream
step
sever
opportun
drugresist
virus
aris
undergo
select
pressur
initi
infect
inoculum
ffumous
use
studi
contain
sever
virus
particular
point
mutat
robust
amplif
step
occur
initi
inoculum
seed
thousand
individu
macrophag
dendrit
cell
viral
genom
begin
amplifi
diversifi
new
drugresist
variant
aris
period
must
presenc
drugsuscept
product
made
parent
sibl
genom
step
box
fig
suppress
yield
total
drugresist
viru
rna
supernat
calcul
describ
fig
proport
drugresist
rna
determin
restrict
digest
pcr
product
fig
data
shown
averag
result
standard
deviat
two
three
biolog
replic
growth
drugresist
virus
accomplish
choic
domin
drug
target
build
block
dengu
viru
nucleocapsid
assemblag
thought
preassembl
dimer
core
protein
observ
solut
interestingli
mutat
confer
resist
coretarget
antivir
compound
locat
dimer
interfac
fig
suggest
mutant
wildtyp
protein
capabl
form
higherord
oligom
presenc
absenc
drug
wildtyp
core
protein
mix
infect
exhibit
similar
fraction
pattern
even
pattern
chang
presenc
fig
thu
like
oligom
form
either
presenc
absenc
drug
contain
drugresist
drugsuscept
core
protein
drugsuscept
virus
found
domin
inhibitor
drugresist
virus
deliber
coinfect
perform
singl
infecti
cycl
cultur
cell
fig
even
ratio
signific
inhibit
drugresist
viral
growth
coinfect
drugsuscept
viru
observ
assum
random
assembl
argu
much
oligomer
assemblag
core
protein
compos
drugresist
subunit
remain
phenotyp
drug
suscept
ratio
certainli
underestim
effect
would
seen
actual
infect
would
much
like
drugresist
variant
creat
cell
alreadi
contain
dozen
hundr
drugsuscept
genom
find
phenotyp
domin
drugsuscept
genom
mark
contrast
situat
observ
nucleosid
inhibitor
dengu
viru
rna
replic
case
presenc
drugsuscept
virus
found
effect
growth
drugresist
virus
mani
coinfect
condit
cultur
fig
intrigu
two
mutat
confer
resist
identifi
work
map
methyltransferas
domain
fig
methyltransferas
polymeras
domain
known
interact
function
structur
thu
possibl
either
mutat
exert
alloster
effect
polymeras
activ
site
inhibit
methyltransferas
activ
directli
whatev
particular
step
rna
synthesi
inhibit
appear
domin
drug
target
possibl
aspect
function
rna
bind
elong
transloc
target
first
cycl
infect
dissemin
drugresist
virus
could
principl
select
viral
spread
within
anim
fig
one
mechan
might
thwart
viral
spread
predomin
local
drugresist
viru
escap
first
infect
cell
infect
neighbor
cell
compani
drugsuscept
rel
day
viral
growth
dengu
virusinfect
mice
select
virus
observ
even
though
circumst
resist
nucleosid
inhibitor
increas
significantli
fig
although
possibl
mutat
lead
resist
frequent
gener
virus
show
reduc
fit
mous
hypothes
seem
unlik
gener
mutant
viru
requir
singl
nucleotid
chang
wildtyp
viru
readili
select
low
moi
cultur
cell
instead
argu
mechan
suppress
viru
mous
observ
tissu
cultur
continu
suppress
drug
resist
day
infect
could
indic
viral
spread
local
might
occur
lymph
node
spleen
present
report
describ
applic
concept
domin
drug
target
initi
describ
polioviru
dengu
viru
categori
pathogen
current
treatment
exist
intracellular
replic
cycl
dengu
viru
differ
polioviru
sever
way
relev
efficaci
domin
drug
target
dengu
viru
envelop
viru
continu
bud
infect
cell
therefor
intracellular
copi
number
viral
genom
product
like
lower
polioviru
rna
replic
complex
dengu
viru
sequest
within
endoplasm
reticulum
invagin
might
preclud
access
product
sibl
genom
nonetheless
domin
suscept
argu
core
protein
encod
differ
genom
interact
directli
creation
domin
inhibitor
drugresist
virus
famili
macabr
novel
applic
quasispeci
concept
implement
use
domin
drug
target
reduc
number
drug
necessari
efficaci
inhibit
viral
infect
babi
hamster
kidney
cell
clone
cultur
monolay
dulbecco
modifi
eagl
medium
supplement
volvol
calf
serum
unit
penicillinml
g
streptomycinml
mm
hepe
ph
co
aed
albopictu
cell
cultur
monolay
leibovitz
medium
supplement
mm
hepe
ph
unit
penicillinml
g
streptomycinml
volvol
fetal
bovin
serum
dengu
viru
serotyp
propag
infecti
cdna
clone
gift
eva
harri
univers
california
berkeley
origin
develop
kinney
et
al
dengu
viru
serotyp
also
gener
infecti
cdna
gift
sujan
shresta
la
jolla
institut
allergi
immunolog
virus
grown
cell
titer
determin
cell
mous
experi
viru
concentr
ultracentrifug
g
h
resuspend
cold
endotoxinfre
phosphatebuff
salin
supplement
fetal
bovin
serum
compound
antibodi
purchas
carbosynth
san
diego
ca
purchas
chembridg
corpor
san
diego
ca
antidengu
virion
antibodi
recogn
four
serotyp
dengu
viru
purchas
abcam
cambridg
anticor
antibodi
kind
gift
andrea
gamarnik
instituto
leloir
argentina
dehydrogenas
gapdh
antilamin
ac
antibodi
purchas
santa
cruz
biotechnolog
santa
cruz
ca
antimitofilin
antibodi
purchas
proteintech
chicago
il
plasmid
rna
transcript
viral
cdna
manipul
gener
infecti
rna
tissu
cultur
experi
describ
elsewher
silent
mutat
core
protein
region
genom
introduc
aflii
restrict
site
wildtyp
genom
drug
resist
mutat
introduc
use
quikchang
sitedirect
mutagenesi
kit
agil
technolog
santa
clara
ca
mous
experi
serotyp
strain
use
envelop
muta
tion
confer
increas
pathogen
dengu
virussuscept
ifnar
ifngr
mice
introduc
describ
amplifi
dna
segment
sequenc
entireti
ensur
adventiti
mutat
introduc
reintroduc
infecti
cdna
backbon
gener
infecti
rna
describ
mateo
et
al
cell
fraction
protein
precipit
quantit
fraction
cultur
cell
perform
use
qproteom
cell
fraction
kit
qiagen
valencia
ca
follow
manufactur
instruct
protein
fraction
methanol
precipit
resuspend
urea
mm
trishcl
buffer
ph
quantifi
use
dc
protein
assay
kit
biorad
hercul
ca
immunoblot
cell
lysat
separ
gel
electrophoresi
sdspolyacrylamid
gel
transfer
immobilon
polyvinyliden
difluorid
pvdf
membran
millipor
billerica
min
v
miniprotean
iii
transfer
tank
biorad
hercul
ca
immunoblot
incub
anticor
antibodi
dilut
follow
incub
alkalin
phosphataseconjug
goat
antirabbit
immunoglobulin
jackson
immunoresearch
west
grove
pa
dilut
immunoblot
imag
phosporimag
biorad
band
quantit
conduct
imagequ
softwar
biorad
rna
transfect
rna
extract
qrtpcr
method
use
rna
transfect
cell
qrtpcr
assay
describ
elsewher
determin
proport
afliimark
unmark
genom
supernat
infect
cell
use
extract
viral
rna
describ
mateo
et
al
total
rna
use
templat
bulk
rtpcr
superscript
iii
onestep
rtpcr
system
platinum
taq
invitrogen
grand
island
ny
follow
primer
forward
cgtggaccgacaaagacagattctt
revers
cttgtctgc
tgacgatcatgtgtg
result
amplicon
purifi
use
nucleospin
extract
ii
pcr
cleanup
kit
machereynagel
deer
park
ny
digest
aflii
result
product
run
agarosetrisborateedta
tbe
gel
quantifi
use
alphaimag
ep
softwar
alphainnotech
san
jose
ca
infect
assay
viru
titrat
conduct
cell
describ
mateo
et
al
determin
titer
resist
virus
popul
analyz
polymeras
inhibitor
resuspend
dimethyl
sulfoxid
dmso
ad
overlay
final
concentr
viral
adsorpt
period
core
inhibitor
also
resuspend
dmso
ad
final
concentr
h
viral
adsorpt
final
dmso
concentr
kept
volvol
drug
passag
total
bhk
cell
tissu
cultur
dish
pretreat
increas
concentr
indic
dmso
neg
control
min
infect
two
independ
pool
moi
less
ffucel
briefli
ml
viru
dmem
plu
bovin
serum
appli
cell
plate
incub
h
follow
infect
medium
without
ad
h
supernat
cell
harvest
supernat
use
infect
fresh
monolay
bhk
cell
cycl
repeat
passag
use
moi
less
ffu
per
cell
passag
increas
concentr
pool
viral
rna
result
popul
sequenc
mous
infect
ifnar
ifngr
mice
obtain
harri
greenberg
stanford
univers
school
medicin
mmjax
mice
obtain
mmrrcjax
backcross
addit
five
gener
mice
jackson
laboratori
bar
harbor
mate
j
mice
jackson
laboratori
bar
harbor
gener
ifnar
ifngr
mice
mice
bred
hous
specificpathogenfre
condit
stanford
univers
aaalacaccredit
vivarium
ifnar
ifngr
ifnar
ifngr
mous
coloni
monitor
adventiti
viral
bacteri
parasit
pathogen
dirtybed
sentinel
sentinel
test
everi
month
found
free
mous
parvoviru
minut
viru
mice
mous
hepat
viru
mous
rotaviru
edim
theiler
murin
encephalomyel
viru
murin
noroviru
sendai
viru
mous
adenoviru
ectromelia
mousepox
lymphocyt
choriomening
viru
pneumonia
viru
mice
respiratori
enteroviru
iii
mycoplasma
pulmoni
helicobact
spp
pasteurella
pneumotropica
fur
mite
lice
pinworm
mice
hous
individu
ventil
cage
provid
irradi
cage
bed
irradi
food
uvirradi
acidifi
water
experi
approv
stanford
institut
anim
care
use
committe
administr
panel
laboratori
anim
care
agematch
mice
week
age
use
experi
total
ffu
viru
inject
retroorbit
anesthet
mice
volum
l
mice
hous
anim
biosafeti
level
condit
drug
treatment
perform
oral
drug
treatment
ifnar
ifngr
mice
stock
carbosynth
san
diego
ca
prepar
drug
resuspens
salin
concentr
achiev
dose
mgkg
chembridg
corpor
san
diego
ca
prepar
concentr
aqueou
solut
contain
sigma
st
loui
mo
result
dose
mgkg
drug
deliv
oral
gavag
l
drug
solut
vehiclemous
everi
h
h
spleen
sampl
collect
ex
vivo
viral
popul
amplif
viral
popul
spleen
mice
treat
vehicl
drug
use
ex
vivo
amplif
infect
fresh
monolay
cell
presenc
drug
dmso
infect
allow
proceed
h
supernat
harvest
titer
determin
viral
rna
extract
quantifi
describ
statist
analysi
data
analyz
prism
softwar
graphpad
softwar
inc
statist
signific
determin
use
twotail
pair
test
experi
cultur
cell
mannwhitney
test
data
illustr
fig
